GLPG-5101 Market Summary

Key Factors Driving GLPG-5101 Growth

1. High complete-response rates in indolent NHL

In the ATALANTA-1 Phase I/II study, results reported at the 2025 International Conference on Malignant Lymphoma showed that 31 of 32 infused patients (97%) with relapsed/refractory indolent NHL achieved complete response. All 10 evaluable patients assessed for minimal residual disease were negative at the time of complete response. The 12-month progression-free survival rate was 97%. These results suggested substantial clinical potential, but the small cohort and early-stage study design limit comparisons with approved CAR-T therapies.

2. Encouraging results in mantle cell lymphoma

In the MCL cohort, data reported in December 2025 showed an objective response rate of 100% (24/24 patients) and a complete-response rate of 96%. At a median follow-up of nine months, duration-of-response and progression-free-survival rates were both 83%. These findings supported further investigation in a heavily pretreated population with substantial unmet need. However, they were preliminary data from a small study and did not establish comparative efficacy or regulatory approval.

3. Rapid, decentralized manufacturing

GLPG-5101 was designed to be manufactured close to treatment centres, reducing the time between cell collection and infusion. In the indolent NHL cohort, 28 of 32 infused patients (93%) received treatment within seven days of leukapheresis, and 30 patients received fresh, non-cryopreserved product. This rapid vein-to-vein process could reduce the need for bridging chemotherapy and improve access for patients whose disease may progress while awaiting treatment.

4. FDA Regenerative Medicine Advanced Therapy (RMAT) designation

In August 2025, the US FDA granted GLPG-5101 RMAT designation for relapsed/refractory MCL. This designation can facilitate development and regulatory interactions for regenerative medicine therapies addressing serious conditions. It reflected preliminary clinical evidence considered promising enough to support accelerated development discussions, but it did not constitute marketing authorization or guarantee approval.

5. Potential for durable CAR-T cell persistence and a favorable safety profile

In the indolent NHL study, CAR-T cells remained detectable in evaluable patients at nine months, with persistence observed for up to 21 months. The company also reported low rates of severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), with no deaths in that cohort at the reported data cut-off. If confirmed in larger studies, durable cell persistence and manageable toxicity could support clinical adoption. The limited sample size and follow-up, however, prevent definitive conclusions about long-term safety and durability.

GLPG-5101 Recent Developments

In August 2025, the US Food and Drug Administration granted GLPG-5101 Regenerative Medicine Advanced Therapy (RMAT) designation for relapsed or refractory mantle cell lymphoma, supporting its continued development.

“GLPG-5101 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of GLPG-5101 for potential indication like Burkitt’s lymphoma, Diffuse large B cell lymphoma, Follicular lymphoma, Lymphoid leukaemia, Mantle-cell lymphoma, Non-Hodgkin’s lymphoma, and Systemic lupus erythematosus in the 7MM. A detailed picture of GLPG-5101’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the GLPG-5101 for potential indications. The GLPG-5101 market report provides insights about GLPG-5101’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current GLPG-5101 performance, future market assessments inclusive of the GLPG-5101 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of GLPG-5101 sales forecasts, along with factors driving its market.

GLPG-5101 Drug Summary

GLPG-5101 is an investigational, second-generation autologous CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy developed by Galapagos NV for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) and other aggressive B-cell malignancies. The therapy uses genetically modified T cells collected from the patient to express a CAR that recognizes CD19, a protein found on the surface of B cells, enabling the engineered cells to identify and destroy malignant B cells. Its CAR construct incorporates a 4-1BB costimulatory domain designed to support T-cell activation, proliferation, and persistence. GLPG-5101 is manufactured using Galapagos’ decentralized, near-point-of-care cell therapy platform, which aims to shorten manufacturing and delivery timelines and preserve early-memory T-cell characteristics associated with cellular expansion and durability. The manufacturing approach is designed to achieve a median vein-to-vein time of approximately seven days, potentially reducing the period patients must wait for treatment compared with conventional centralized CAR-T manufacturing. The therapy is administered as a single intravenous infusion following lymphodepleting chemotherapy, according to the clinical protocol. Its safety, efficacy, and manufacturing feasibility are being evaluated in the Phase I/II ATALANTA-1 clinical trial across multiple B-cell malignancies, including diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The report provides GLPG-5101’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the GLPG-5101 Market Report

The report provides insights into:

• A comprehensive product overview including the GLPG-5101 MoA, description, dosage and administration, research and development activities in potential indication like Burkitt’s lymphoma, Diffuse large B cell lymphoma, Follicular lymphoma, Lymphoid leukaemia, Mantle-cell lymphoma, Non-Hodgkin’s lymphoma, and Systemic lupus erythematosus.
• Elaborated details on GLPG-5101 regulatory milestones and other development activities have been provided in GLPG-5101 market report.
• The report also highlights GLPG-5101‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The GLPG-5101 market report also covers the patents information, generic entry and impact on cost cut.
• The GLPG-5101 market report contains current and forecasted GLPG-5101 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The GLPG-5101 market report also features the SWOT analysis with analyst views for GLPG-5101 in potential indications.

Methodology

The GLPG-5101 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

GLPG-5101 Analytical Perspective by DelveInsight

• In-depth GLPG-5101 Market Assessment

This GLPG-5101 sales market forecast report provides a detailed market assessment of GLPG-5101 for potential indication like Burkitt’s lymphoma, Diffuse large B cell lymphoma, Follicular lymphoma, Lymphoid leukaemia, Mantle-cell lymphoma, Non-Hodgkin’s lymphoma, and Systemic lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted GLPG-5101 sales data uptil 2034.

• GLPG-5101 Clinical Assessment

The GLPG-5101 market report provides the clinical trials information of GLPG-5101 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

GLPG-5101 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

GLPG-5101 Market Potential & Revenue Forecast

• Projected market size for the GLPG-5101 and its key indications
• Estimated GLPG-5101 sales potential (GLPG-5101 peak sales forecasts)
• GLPG-5101 Pricing strategies and reimbursement landscape

GLPG-5101 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• GLPG-5101 Market positioning compared to existing treatments
• GLPG-5101 Strengths & weaknesses relative to competitors

GLPG-5101 Regulatory & Commercial Milestones

• GLPG-5101 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

GLPG-5101 Clinical Differentiation

• GLPG-5101 Efficacy & safety advantages over existing drugs
• GLPG-5101 Unique selling points

GLPG-5101 Market Report Highlights

• In the coming years, the GLPG-5101 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The GLPG-5101 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence GLPG-5101’s dominance.
• Other emerging products for Burkitt’s lymphoma, Diffuse large B cell lymphoma, Follicular lymphoma, Lymphoid leukaemia, Mantle-cell lymphoma, Non-Hodgkin’s lymphoma, and Systemic lupus erythematosus are expected to give tough market competition to GLPG-5101 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of GLPG-5101 in potential indications.
• Analyse GLPG-5101 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted GLPG-5101 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of GLPG-5101 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of GLPG-5101? How strong is GLPG-5101’s clinical and commercial performance?
• What is GLPG-5101’s clinical trial status in each individual indications such as Burkitt’s lymphoma, Diffuse large B cell lymphoma, Follicular lymphoma, Lymphoid leukaemia, Mantle-cell lymphoma, Non-Hodgkin’s lymphoma, and Systemic lupus erythematosus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the GLPG-5101 Manufacturers?
• What are the key designations that have been granted to GLPG-5101 for potential indications? How are they going to impact GLPG-5101’s penetration in various geographies?
• What is the current and forecasted GLPG-5101 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of GLPG-5101 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to GLPG-5101 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is GLPG-5101? What is the duration of therapy and what are the geographical variations in cost per patient?